HCV inhibitor and therapeutic agent combinations
View Patent ↗The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.
1. A combination product for treating or ameliorating HCV (hepatitis C virus) infection or disorders or symptoms associated therewith in a subject in need thereof comprising a HCV inhibitor selected from:
or an enantiomer, steroisomer, diastereomer, racemic, tautomeric, ester, solvate, hydrate, isotopologue or salt form thereof
and an HCV protease inhibitor which is:
N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-N-{(1S,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide.
2. The product of claim 1 , further comprising one or more different therapeutic agents selected from a HCV inhibitor, a HCV protease inhibitor, a nucleoside or non-nucleoside HCV polymerase inhibitor, a nonpegylated interferon, a pegylated interferon or another anti-HCV agent.
3. The product of claim 2 , wherein the one or more different HCV protease inhibitor therapeutic agents is selected from a NS2 protease inhibitor, a NS3 protease inhibitor, a peptide or dipeptide NS3 protease inhibitor or a NS4a protease cofactor inhibitor.
4. The product of claim 2 , wherein the effective amount of each of the HCV inhibitor and one or more therapeutic agents is in a range of from about 0.1 μg to about 4.5 g per day.